PARs in the inflammation-cancer transformation of CRC

Clin Transl Oncol. 2023 May;25(5):1242-1251. doi: 10.1007/s12094-022-03052-x. Epub 2022 Dec 22.

Abstract

Colorectal cancer (CRC) is one of the common malignancies with a global trend of increasing incidence and mortality. There is an urgent need to identify new predictive markers and therapeutic targets for the treatment of CRC. Protease-activated receptors (PARs) are a class of G-protein-coupled receptors, with currently identified subtypes including PAR1, PAR2, PAR3 and PAR4. Increasingly, studies suggest that PARs play an important role in the growth and metastasis of CRC. By targeting multiple signaling pathways may contribute to the pathogenesis of CRC. In this review, we first describe recent studies on the role of PARs in CRC inflammation-cancer transformation, focusing on the important role of PARs in signaling pathways associated with inflammation-cancer transformation, and summarize the progress of research on PARs-targeted drugs.

Keywords: Colitis-associated cancer; Colorectal cancer; Inflammatory-cancer transformation; Protease-activated receptor.

Publication types

  • Review

MeSH terms

  • Humans
  • Inflammation
  • Neoplasms*
  • Receptors, Proteinase-Activated* / metabolism
  • Receptors, Thrombin / metabolism
  • Signal Transduction

Substances

  • Receptors, Proteinase-Activated
  • Receptors, Thrombin